Not only this, although the docetaxel treatment reduces EGFR activation by inhibiting its being phosphorylated in the presence of EGF (43), the abnormal activation, mutation, and overexpression of EGFR played a vital role in the establishment of docetaxel resistance in tumor cells as well as PCa cells (11, 44–46). This evidence concerns the gene EGFR and neoplasm.